GT Biopharma logo

GT Biopharma (GTBP) Q1 2026 Earnings

GTBP·Reported May 15, 2026·Before market open

Diluted EPS came in at $-0.11 (+85.5% YoY), missed the $-0.08 consensus by $0.03.

Diluted EPS
$-0.11missed by $0.03
Consensus: $-0.08
SEC

SEC Filings

Earnings release8-K not filed yet

Financial Snapshot

Trailing eight quarters through Q1 2026

Q1 2026 Earnings FAQ

Common questions about GT Biopharma's Q1 2026 earnings report.

GT Biopharma (GTBP) reported Q1 2026 earnings on May 15, 2026 before market open.

GT Biopharma reported diluted EPS of $-0.11 for Q1 2026.

EPS missed the consensus estimate of $-0.08 by $0.03.

Compared to the same quarter a year prior, diluted EPS grew 85.5% from $-0.76.

You can read the 10-Q periodic report (0001493152-26-023346) directly on SEC EDGAR. The filing index links above go to sec.gov.